Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axitinib ophthalmic - Clearside Biomedical

Next Previous
X
Search
Drug Profile

Axitinib ophthalmic - Clearside Biomedical

Alternative Names: Axitinib injectable suspension - Clearside Biomedical; CLS 1002; CLS-AX; CLS011A

Latest Information Update: 14 Mar 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clearside Biomedical
  • Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 06 Mar 2025 Clearside Biomedical complets an End-of-Phase II meeting with the US FDA for Wet age-related macular degeneration (AMD)
  • 12 Nov 2024 Clearside Biomedical plans an end-of-phase II meeting with the US FDA for phase III trial for Wet age-related macular degeneration in early 2025
  • 09 Oct 2024 Efficacy and adverse events data from phase-IIb ODYSSEY trial in Wet age related macular degeneration released by Clearside Biomedical

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top